A report published in Nature Medicine has shown that an RNA antisense oligonucleotide (AON) treatment, directed to the CEP290 gene for LCA10, found one patient… Read More »Leber congenital amaurosis (LCA) reports a sustained improvement for the treatment of a novel anti-oligonucleotide (AON) therapy.
AsciepiX Therapeutics Inc., based in Baltimore, Maryland, has announced that the first patient has been dosed in the Phase 1/2a “CONGO” clinical trial to evaluate… Read More »AsclepiX Therapeutics Inc. has reported the first dose of a novel peptide treatment in Phase 1/2a for Diabetic Macular Edema (DME)
Researchers at the Department of Ophthalmology, Ludwig-Maximilians-University, Munich, have reported results on novel engineered viral vectors aimed to efficiently target photoreceptors. The research used a… Read More »Novel engineered vectors (recombinant adeno-associated virus [vAAV]) may provide efficient targeting for photoreceptors avoiding risks of collateral damage.
Dear EURETINA Members, A very warm welcome to the April 1st, 2021 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA are delighted to… Read More »April 1st, 2021: “EURETINA-Brief”© Issue No. 232
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the December 18th, 2019 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »December 18th, 2019: “EURETINA-Brief”© Issue No. 204
Genetics and Genomics of Eye Disease, 1st Edition – Advancing to Precision Medicine (Elsevier) Editors: Xiaoyi Gao Paperback ISBN: 9780128162224 eBook ISBN: 9780128167274; Pages 383,… Read More »Genetics and Genomics of Eye Disease, 1st Edition – Advancing to Precision Medicine (Elsevier) Editors: Xiaoyi Gao Ph.D.
Researchers at the Sydney Institute of Vision Science, in New South Wales, Australia report that good long-term efficacy of anti-VEGF therapy over 5 years provides… Read More »Five-year outcomes of retinal vein occlusion provide long term data for anti-VEGF treatments on real-world data
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the April 16th, 2019 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »April 16th, 2019: “EURETINA-Brief” Issue No. 190
Editas Medicine, Inc. (NASDAQ: EDIT), based in Dublin, Ireland and Cambridge, Massachusetts, and Allergan plc (NYSE: AGN), also headquartered in Dublin, Ireland have announced the… Read More »Editas Medicine Inc. (NASDAQ:EDIT), and Allergan plc (NYSE:AGN), progress option rights to develop CRISPR technology for treatment of LCA 10
EURETINA, through a collaboration with Fight for Sight, have announced a dedicated Research Call to support clinical research in the field of sub-macular haemorrhage (SMH),… Read More »***EURETINA / Fight for Sight launch Sub-Macular Haemorrhage (SMH) Clinical Research Call***